Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/16/2021 | $14.00 → $12.00 | Buy | Needham |
| 11/16/2021 | $17.00 → $15.00 | Outperform | Oppenheimer |
| 11/1/2021 | $11.00 | Buy | Alliance Global Partners |
EFFECT - Gamida Cell Ltd. (0001600847) (Filer)
EFFECT - Gamida Cell Ltd. (0001600847) (Filer)
EFFECT - Gamida Cell Ltd. (0001600847) (Filer)
4 - Gamida Cell Ltd. (0001600847) (Issuer)
4 - Gamida Cell Ltd. (0001600847) (Issuer)
4 - Gamida Cell Ltd. (0001600847) (Issuer)
For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p